These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2794934)
1. Association of HLA-DR tissue types with Graves' disease in Taiwan. Tsai KS; Hsieh RP; Chang CC; Chen FW; Lee SC Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):336-41. PubMed ID: 2794934 [TBL] [Abstract][Full Text] [Related]
2. Serological and molecular studies of HLA in Sardinian patients with Graves' disease. La Nasa G; Martino E; Carcassi C; Mulargia M; Floris L; Vacca A; Baldini G; Orrù S; Ledda A; Grasso L Dis Markers; 1991; 9(6):307-12. PubMed ID: 1823309 [TBL] [Abstract][Full Text] [Related]
3. HLA Bw46 and DR9 associations in Graves' disease of Chinese patients are age- and sex-related. Yeo PP; Chan SH; Thai AC; Ng WY; Lui KF; Wee GB; Tan SH; Lee BW; Wong HB; Cheah JS Tissue Antigens; 1989 Sep; 34(3):179-84. PubMed ID: 2595722 [TBL] [Abstract][Full Text] [Related]
4. HLA-DQ3 is associated with Graves' disease in African-Americans. Ofosu MH; Dunston G; Henry L; Ware D; Cheatham W; Brembridge A; Brown C; Alarif L Immunol Invest; 1996; 25(1-2):103-10. PubMed ID: 8675226 [TBL] [Abstract][Full Text] [Related]
5. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. Inaba H; Martin W; De Groot AS; Qin S; De Groot LJ J Clin Endocrinol Metab; 2006 Jun; 91(6):2286-94. PubMed ID: 16595602 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers. Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192 [TBL] [Abstract][Full Text] [Related]
7. [The effects of HLA class II genes on the susceptibility to autoimmune thyroid diseases]. Shinagawa H Fukuoka Igaku Zasshi; 1990 Feb; 81(2):97-111. PubMed ID: 2328940 [TBL] [Abstract][Full Text] [Related]
8. HLA-DR associations with Graves' disease in eastern Hungary. Stenszky V; Kozma L; Balazs C; Farid NR Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983 [TBL] [Abstract][Full Text] [Related]
9. Studies of restriction fragment length polymorphism (RFLP) of DR and DQ genes in HLA-DR3 positive patients with Graves' disease or systemic lupus erythematosus. Garcia-Ameijeiras A; Gladman DD; Chan JY; Volpé R Clin Invest Med; 1993 Oct; 16(5):326-32. PubMed ID: 7903231 [TBL] [Abstract][Full Text] [Related]
10. HLA and Graves' disease: an association with HLA-DRw3. Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B J Clin Endocrinol Metab; 1980 Oct; 51(4):863-7. PubMed ID: 6932402 [TBL] [Abstract][Full Text] [Related]
11. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. Heward JM; Allahabadia A; Daykin J; Carr-Smith J; Daly A; Armitage M; Dodson PM; Sheppard MC; Barnett AH; Franklyn JA; Gough SC J Clin Endocrinol Metab; 1998 Oct; 83(10):3394-7. PubMed ID: 9768636 [TBL] [Abstract][Full Text] [Related]
12. Class II major histocompatibility complex antigen expression and cellular interactions in thyroid glands of Graves' disease. Matsunaga M; Eguchi K; Fukuda T; Kurata A; Tezuka H; Shimomura C; Otsubo T; Ishikawa N; Ito K; Nagataki S J Clin Endocrinol Metab; 1986 Apr; 62(4):723-8. PubMed ID: 3081570 [TBL] [Abstract][Full Text] [Related]
13. Effect of removing human Graves' thyroid xenografts after eight weeks in nude mice and rexenografting them into SCID mice. Yoshikawa N; Arreaza G; Morita T; Mukuta T; Resetkova E; Akasu F; Miller N; Jamieson C; Volpé R J Clin Endocrinol Metab; 1994 Feb; 78(2):367-74. PubMed ID: 8106624 [TBL] [Abstract][Full Text] [Related]
14. Lack of an independent association between the human leukocyte antigen allele DQA1*0501 and Graves' disease. Cuddihy RM; Bahn RS J Clin Endocrinol Metab; 1996 Feb; 81(2):847-9. PubMed ID: 8636314 [TBL] [Abstract][Full Text] [Related]
15. The role of HLA antigens in the manifestation and course of Graves' disease. Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758 [TBL] [Abstract][Full Text] [Related]
16. [Graves' disease. Predominance of the DRw3 antigen (author's transl)]. Allanic H; Fauchet R; Lorcy Y; Heim J; Guéguen M; Leguerrier AM; Genetet B Nouv Presse Med; 1980 Jun; 9(26):1823-6. PubMed ID: 6893077 [TBL] [Abstract][Full Text] [Related]
17. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease. Kraemer MH; Donadi EA; Tambascia MA; Magna LA; Prigenzi LS Immunol Invest; 1998; 27(1-2):17-29. PubMed ID: 9561915 [TBL] [Abstract][Full Text] [Related]
18. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis. Skanes VM; Barnard J; Farid N; Marshall WH; Murphy L; Rideout D; Taylor R; Xidos G; Larsen B Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234 [TBL] [Abstract][Full Text] [Related]
19. Graves' disease and HLA: clinical and epidemiologic associations. Farid NR; Stone E; Johnson G Clin Endocrinol (Oxf); 1980 Dec; 13(6):535-44. PubMed ID: 6894412 [TBL] [Abstract][Full Text] [Related]
20. Correlation of HLA types and clinical findings in Japanese patients with hyperthyroid Graves' disease: evidence indicating the existence of four subpopulations. Inoue D; Sato K; Enomoto T; Sugawa H; Maeda M; Inoko H; Tsuji K; Mori T; Imura H Clin Endocrinol (Oxf); 1992 Jan; 36(1):75-82. PubMed ID: 1559302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]